INTEGRA Biosciences is excited to welcome Line Stigen Raquet as a non-executive board member. Line has over 20 years’ leadership experience in the life sciences sectors, and her extensive business knowledge will contribute to INTEGRA’s continued growth. Line is a biochemist, and her education and training have given her a firm foundation for success as an entrepreneur in various life sciences markets.
Throughout her illustrious career to date, Line has demonstrated her competency in commercial and P&L functions at several major industry players – including Life Technologies, QIAGEN, Mettler Toledo and Malvern Panalytical – acquiring a deep knowledge of diagnostics, laboratory automation and drug discovery. Line has been the CEO of several companies, including Creoptix AG, a next-generation company developing bioanalytical solutions for drug discovery, which was successfully sold to Spectris plc in 2022. Most recently, Line was also CEO of Nanolive SA, a leading label-free live cell imaging and analysis company.
Line will fill the position recently vacated by Elmar Morscher, former CEO of INTEGRA. Elmar, together with 2 partners, founded Tecuria Engineering in 1988, which merged with INTEGRA in December 2001. He became CEO in January 2002, and held this role until the end of 2019, when he resigned and joined the board.
Elmar has been invaluable in ensuring INTEGRA’s success over the last 2 decades, transforming it from a small start-up to a leading international manu.
